Patents by Inventor Michael Gimbrone
Michael Gimbrone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070184466Abstract: The present invention is based upon the discovery that endothelial cells exposed to atheroprotectiveflow increase expression of the transcription factor KLF2 via a distinct flow-mediated signaling pathway and that this, in turn, modulates the activity of a series of genes that are responsible for maintaining the cells in an atherosclerosis-resistant state. By carrying out analyses to determine the extent to which endothelial cells are expressing these genes, a determination can be made concerning whether they are in a healthy state and factors can be examined for their effect on this state. In addition, the invention includes microarray plates or slides that can be used in carrying out such analyses.Type: ApplicationFiled: November 15, 2006Publication date: August 9, 2007Applicant: The Brigham and Women's Hospital, Inc.Inventors: Guillermo Garcia-Cardena, Michael Gimbrone, Kush Parmar
-
Patent number: 7163808Abstract: Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g.Type: GrantFiled: November 20, 2001Date of Patent: January 16, 2007Assignees: California Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Jr., Hai U. Wang
-
Patent number: 6759210Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: March 28, 1997Date of Patent: July 6, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Publication number: 20040081992Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: September 3, 2003Publication date: April 29, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone
-
Publication number: 20030188327Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: July 2, 2002Publication date: October 2, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone
-
Publication number: 20030097668Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, advanced atherosclerosis/plaque rupture, ischemia/reperfusion, hypertension, restenosis, cardiac calcification, allo/xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: February 8, 2002Publication date: May 22, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Katherine Galvin, Dean A. Falb, Michael J. Donovan, Dennis Huszar, Michael A. Gimbrone
-
Patent number: 6534641Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: March 28, 1997Date of Patent: March 18, 2003Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6492126Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: August 11, 1999Date of Patent: December 10, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Publication number: 20020178458Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: November 9, 2001Publication date: November 28, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone
-
Publication number: 20020170077Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: October 5, 2001Publication date: November 14, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone
-
Publication number: 20020142441Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: August 7, 2001Publication date: October 3, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone
-
Publication number: 20020136726Abstract: Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g.Type: ApplicationFiled: November 20, 2001Publication date: September 26, 2002Applicant: California Institute of TechnologyInventors: David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone, Hai U. Wang
-
Publication number: 20020137700Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: August 11, 1999Publication date: September 26, 2002Inventors: DEAN A. FALB, MICHAEL A. GIMBRONE
-
Publication number: 20020102603Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: August 11, 1999Publication date: August 1, 2002Inventors: DEAN A. FALB, MICHAEL A. GIMBRONE
-
Publication number: 20020034736Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: ApplicationFiled: June 6, 1997Publication date: March 21, 2002Inventors: DEAN A. FALB, Michael A. Gimbrone
-
Patent number: 6359194Abstract: The present invention is based on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-&bgr; signaling pathways. Such transgenic mice may be used for screening compounds that may potentially useful for treating or preventing cardiovascular disease.Type: GrantFiled: April 8, 1999Date of Patent: March 19, 2002Assignees: Millennium Pharmaceuticals, Inc., Brigham & Women's HospitalInventors: Katherine Galvin, Dean A. Falb, Michael J. Donovan, Dennis Huszar, Michael A. Gimbrone, Jr.
-
Patent number: 6225084Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: September 9, 1997Date of Patent: May 1, 2001Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6221628Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: September 8, 1997Date of Patent: April 24, 2001Assignees: Brigham & Women's Hospital, Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6124433Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: September 26, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.
-
Patent number: 6087477Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: October 6, 1997Date of Patent: July 11, 2000Assignees: Millennium Pharmaceuticals, Inc., Brigham and Women's HospitalInventors: Dean A. Falb, Michael A. Gimbrone, Jr.